Treatment with Adakveo (crizanlizumab) did not reduce the yearly occurrence of painful vaso-occlusive crises (VOCs) leading to a medical visit, as compared with a placebo, in people with sickle cell disease (SCD), according to preliminary data from an ongoing Phase 3 trial. The study, called STAND (NCT03814746), is…
News
Good oral health is essential in people with sickle cell anemia (SCA), according to a new study from Saudi Arabia that found that several disease-causing bacteria species — including Enterobacteriaceae — were significantly more abundant in a group of patients with poorer dental health than…
People with sickle cell disease (SCD) may see their physical, mental, and social health get better after a stem cell transplant, and this may help them pursue their personal life goals, a small study found. Still, challenges remained as they “confronted a new and unfamiliar reality,” the researchers…
Continuing its partnership with the Sickle Cell Disease Association of America (SCDAA), medical technology company Hemanext is working with the SCDAA’s Miami chapter to offer community-focused educational programs and local events. Hemanext focuses on improving the quality, safety, efficacy, and cost of blood transfusions, which are often…
To underscore the importance of understanding and getting tested for the sickle cell trait (SCT), the Cayenne Wellness Center has launched a campaign targeting California’s students, school athletes, parents, and educators. The five-year Sickle Cell Trait Awareness Campaign will offer resources that will help educate people about SCT and…
The sickle cell disease (SCD) treatment program at Loma Linda University Children’s Hospital in California has been recognized as a center of excellence, joining dozens of other centers in the U.S. affiliated with the National Alliance for Sickle Cell Centers (NASCC). The NASCC identifies “member” centers based on…
The addition of briquilimab, Jasper Therapeutics’ investigational conditioning therapy, improved the success of a stem cell transplant in people with sickle cell disease (SCD), early data from the first three patients in a Phase 1/2 trial show. According to the company, two of the three patients, all treated…
Adding omega-3 or vitamin D supplements boosts the therapeutic effectiveness of standard of care therapy for sickle cell disease (SCD) children with vaso-occlusive crises (VOCs), a recent study shows. Omega-3 supplements reduced the number and severity of VOCs, while vitamin D lessened their severity only. Supplementation also reduced the…
We at Sickle Cell Anemia News have brought you coverage of the latest developments in research and advances in treatment related to sickle cell disease (SCD) in 2022. We look forward to continuing being a resource for the sickle cell community in 2023. Here we’ve compiled a list of the…
Bluebird bio will resume its study of lovotibeglogene autotemcel (lovo-cel) in children and adolescents with sickle cell disease (SCD) following the U.S. Food and Drug Administration’s (FDA’s) lifting of its yearlong partial clinical hold for patients under age 18. The temporary holdup stemmed from an investigation into…
Recent Posts
- Etavopivat Phase 3 results support potential approval in sickle cell disease
- New diagnoses result in new grief and a new relationship with my body
- Study finds lower treatment use among SCD patients in sub-Saharan Africa
- Outside, looking in: The silent isolation of living with sickle cell disease
- Bias in sickle cell care may be tied to opioid stigma, new study finds
- How I advocate for my health needs while traveling for work
- Brain development changes seen in children with sickle cell anemia
- Beam to seek OK of gene-edited cell therapy risto-cel for sickle cell disease
- Agios to seek accelerated approval in US of oral mitapivat for SCD
- Japanese agency awards $32M to advance sickle cell treatment to trials